PT  - JOURNAL ARTICLE
AU  - Eliseo Albert
AU  - Ignacio Torres
AU  - Felipe Bueno
AU  - Dixie Huntley
AU  - Estefanía Molla
AU  - Miguel Ángel Fernández-Fuentes
AU  - Mireia Martínez
AU  - Sandrine Poujois
AU  - Lorena Forqué
AU  - Arantxa Valdivia
AU  - Carlos Solano de la Asunción
AU  - Josep Ferrer
AU  - Javier Colomina
AU  - David Navarro
TI  - Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for the diagnosis of COVID-19 in primary healthcare centers
AID  - 10.1101/2020.10.16.20213850
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.16.20213850
4099  - http://medrxiv.org/content/early/2020/10/20/2020.10.16.20213850.short
4100  - http://medrxiv.org/content/early/2020/10/20/2020.10.16.20213850.full
AB  - We evaluated the Panbio™ COVID-19 AG Rapid Test Device (RAD) for the diagnosis of COVID-19 in symptomatic patients attended in primary healthcare centers (n=412). Overall specificity and sensitivity of RAD was 100% and 79.6%, respectively, taking RT-PCR as the reference. SARS-CoV-2 could not be cultured from specimens yielding RT-PCR+/RAD- results.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work received no public or private funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study was approved by the Research Ethics Committee of Hospital Clinico Universitario INCLIVA (March 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.